Cargando…
Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial
OBJECTIVE: To compare the analgesic efficacy and safety of acupuncture and lornoxicam in acute renal colic (ARC). DESIGN, SETTING, PARTICIPANT: A randomized, double-blind, parallel-controlled, single-centered trial was conducted at Susong County People’s Hospital from October 2019 to November 2020....
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643168/ https://www.ncbi.nlm.nih.gov/pubmed/34876848 http://dx.doi.org/10.2147/JPR.S339006 |
_version_ | 1784609825679736832 |
---|---|
author | Zhang, Xiaohua Liu, Xinguo Ye, Qiongxiang Wang, Xunbao Chen, Jinjun Wang, Zhiyong Zhao, Pengfei Tao, Baozhou Xu, Guoping Xu, Wanfeng Wu, Kan Xiao, Yao Yang, Li Tian, Junqiang Wang, Juan Dong, Zhilong Wang, Zhiping |
author_facet | Zhang, Xiaohua Liu, Xinguo Ye, Qiongxiang Wang, Xunbao Chen, Jinjun Wang, Zhiyong Zhao, Pengfei Tao, Baozhou Xu, Guoping Xu, Wanfeng Wu, Kan Xiao, Yao Yang, Li Tian, Junqiang Wang, Juan Dong, Zhilong Wang, Zhiping |
author_sort | Zhang, Xiaohua |
collection | PubMed |
description | OBJECTIVE: To compare the analgesic efficacy and safety of acupuncture and lornoxicam in acute renal colic (ARC). DESIGN, SETTING, PARTICIPANT: A randomized, double-blind, parallel-controlled, single-centered trial was conducted at Susong County People’s Hospital from October 2019 to November 2020. Eighty-four patients with ARC were randomly divided into lornoxicam group (Group L) and acupuncture group (Group A). Group A was treated with acupuncture at Sanyinjiao (SP6), Yinlingquan (SP9) and normal saline, and Group L was treated with sham acupuncture at SP6, SP9 and lornoxicam. MAIN OUTCOME MEASURES: Visual analogue scale (VAS) scores and adverse reactions such as nausea and dizziness were recorded within 5, 10, 15, 20 and 40 minutes after treatment. The main outcome of this study was the short-term effective (STE) rate, the secondary outcome was the onset time, and the safety index was incidence of adverse reactions. RESULTS: A total of 80 patients completed this study, including 41 patients (21 males and 20 females) in Group L and 39 patients (21 males and 18 females) in Group A. Group A exhibited lower scores versus group L after treatment (P < 0.05). The overall STE of group L was 61.00% (25/41), significantly lower than group A [84.62% (33/39)] (P < 0.001). There was no difference in the incidence of adverse reactions between group A [2.6% (1/39)] and group L [7.3% (3/41)] (P = 0.616). The ordered logistic regression analysis showed patients receiving acupuncture therapy are more likely to be cured [OR = 2.887, 95% CI: (1.190, 7.000), P = 0.019]. CONCLUSION: Acupuncture at SP6, SP9 and intramuscular injection of lornoxicam can effectively and safely relieve ARC, but the former has faster and better analgesic effect. Moreover, the incidence of adverse reactions was similar between the two treatments. This acupuncture therapy is recommended as a complementary therapy for ARC. |
format | Online Article Text |
id | pubmed-8643168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-86431682021-12-06 Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial Zhang, Xiaohua Liu, Xinguo Ye, Qiongxiang Wang, Xunbao Chen, Jinjun Wang, Zhiyong Zhao, Pengfei Tao, Baozhou Xu, Guoping Xu, Wanfeng Wu, Kan Xiao, Yao Yang, Li Tian, Junqiang Wang, Juan Dong, Zhilong Wang, Zhiping J Pain Res Clinical Trial Report OBJECTIVE: To compare the analgesic efficacy and safety of acupuncture and lornoxicam in acute renal colic (ARC). DESIGN, SETTING, PARTICIPANT: A randomized, double-blind, parallel-controlled, single-centered trial was conducted at Susong County People’s Hospital from October 2019 to November 2020. Eighty-four patients with ARC were randomly divided into lornoxicam group (Group L) and acupuncture group (Group A). Group A was treated with acupuncture at Sanyinjiao (SP6), Yinlingquan (SP9) and normal saline, and Group L was treated with sham acupuncture at SP6, SP9 and lornoxicam. MAIN OUTCOME MEASURES: Visual analogue scale (VAS) scores and adverse reactions such as nausea and dizziness were recorded within 5, 10, 15, 20 and 40 minutes after treatment. The main outcome of this study was the short-term effective (STE) rate, the secondary outcome was the onset time, and the safety index was incidence of adverse reactions. RESULTS: A total of 80 patients completed this study, including 41 patients (21 males and 20 females) in Group L and 39 patients (21 males and 18 females) in Group A. Group A exhibited lower scores versus group L after treatment (P < 0.05). The overall STE of group L was 61.00% (25/41), significantly lower than group A [84.62% (33/39)] (P < 0.001). There was no difference in the incidence of adverse reactions between group A [2.6% (1/39)] and group L [7.3% (3/41)] (P = 0.616). The ordered logistic regression analysis showed patients receiving acupuncture therapy are more likely to be cured [OR = 2.887, 95% CI: (1.190, 7.000), P = 0.019]. CONCLUSION: Acupuncture at SP6, SP9 and intramuscular injection of lornoxicam can effectively and safely relieve ARC, but the former has faster and better analgesic effect. Moreover, the incidence of adverse reactions was similar between the two treatments. This acupuncture therapy is recommended as a complementary therapy for ARC. Dove 2021-11-30 /pmc/articles/PMC8643168/ /pubmed/34876848 http://dx.doi.org/10.2147/JPR.S339006 Text en © 2021 Zhang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Clinical Trial Report Zhang, Xiaohua Liu, Xinguo Ye, Qiongxiang Wang, Xunbao Chen, Jinjun Wang, Zhiyong Zhao, Pengfei Tao, Baozhou Xu, Guoping Xu, Wanfeng Wu, Kan Xiao, Yao Yang, Li Tian, Junqiang Wang, Juan Dong, Zhilong Wang, Zhiping Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial |
title | Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial |
title_full | Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial |
title_fullStr | Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial |
title_full_unstemmed | Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial |
title_short | Acupuncture versus Lornoxicam in the Treatment of Acute Renal Colic: A Randomized Controlled Trial |
title_sort | acupuncture versus lornoxicam in the treatment of acute renal colic: a randomized controlled trial |
topic | Clinical Trial Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643168/ https://www.ncbi.nlm.nih.gov/pubmed/34876848 http://dx.doi.org/10.2147/JPR.S339006 |
work_keys_str_mv | AT zhangxiaohua acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT liuxinguo acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT yeqiongxiang acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT wangxunbao acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT chenjinjun acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT wangzhiyong acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT zhaopengfei acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT taobaozhou acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT xuguoping acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT xuwanfeng acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT wukan acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT xiaoyao acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT yangli acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT tianjunqiang acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT wangjuan acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT dongzhilong acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial AT wangzhiping acupunctureversuslornoxicaminthetreatmentofacuterenalcolicarandomizedcontrolledtrial |